Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19

Dysregulation in neutrophil extracellular trap (NET) formation and degradation may play a role in the pathogenesis and severity of COVID-19; however, its role in the pediatric manifestations of this disease including MIS-C and chilblain-like lesions (CLL), otherwise known as “COVID toes”, remains unclear. Studying multinational cohorts, we found that, in CLL, NETs were significantly increased in serum and skin. There was geographic variability in the prevalence of increased NETs in MIS-C, in association with disease severity. MIS-C and CLL serum samples displayed decreased NET degradation ability, in association with C1q and G-actin or anti-NET antibodies, respectively, but not with genetic variants of DNases. In adult COVID-19, persistent elevations in NETs post-disease diagnosis were detected but did not occur in asymptomatic infection. COVID-19-affected adults displayed significant prevalence of impaired NET degradation, in association with anti-DNase1L3, G-actin, and specific disease manifestations, but not with genetic variants of DNases. NETs were detected in many organs of adult patients who died from COVID-19 complications. Infection with the Omicron variant was associated with decreased levels of NETs when compared to other SARS-CoV-2 strains. These data support a role for NETs in the pathogenesis and severity of COVID-19 in pediatric and adult patients.

for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 CLL has been observed in patients with mild and asymptomatic COVID-19, and post-mRNA SARS-CoV-2 vaccination, but remains controversial as many patients are PCR negative without seroconversion (Kolivras et al., 2022). Chilblains may occur in the type-1 interferonopathies and affected patients with CLL can produce increased IFN-alpha, supporting that this manifestation may be associated with rapid clearance of SARS-CoV-2 infection (Hubiche et al., 2021).
Increased numbers of activated neutrophils have been described in severe COVID-19 and in MIS-C (Agbuduwe and Basu, 2020;Carter et al., 2020). Emerging evidence suggests that excessive neutrophil extracellular trap (NET) formation plays a key role in  pathogenesis. (Barnes et al., 2020;Borges et al., 2020;Veras et al., 2020) NETs are extruded by neutrophils as a meshwork of chromatin bound to granule proteins and are synthesized during various infectious and sterile inflammatory conditions (Brinkmann et al., 2004). Infection with SARS-CoV-2 can trigger NET formation (Middleton et al., 2020). In other conditions, excessive NET formation may cause vascular injury by activating endothelial to mesenchymal transition, triggering death of endothelial cells and vascular smooth muscle cells, and promoting coagulation. (Barbosa et al., 2021;Colmenero et al., 2020;Khaddaj-Mallat et al., 2021;Leppkes et al., 2020;Zuo et al., 2021b) NET complexes have been detected in the circulation of adult patients with severe COVID-19.(Zuo et al., 2020), and widespread occlusion of small vessels by 1 0 analysis (WGS) within a subset of subjects and conducted variant association analysis for genes encoding for enzymes or molecules involved in DNA degradation (DNASE1,DNASE1L3,DNASE1L1,DNASE1L2,DNASE2B,SERPINB1,TREX1 and TREX2). The analysis did not reveal any candidate homozygous rare or low-frequency (MAF< 0.1) variants associated with the non-degrader when compared to the degrader group (Supplementary Table 1). Furthermore, we did not observe heterozygous common (MAF >0.1) variants with distribution attributed to the degrader or non-degrader group (Supplementary Table 1). Overall, a targeted genetic association analysis did not yield evidence associations between genetic alterations in nucleases and impaired NET degradation in the subjects. We therefore investigated other factors that may be involved in aberrant NET degradation.
Complement activation and its deposition in NETs has been linked to impairment in NET degradation. (Leffler et al., 2012;Skendros et al., 2020) PMA-induced healthy ctrl NETs incubated with serum or plasma from MIS-C subjects, but not from CLL or ctrl subjects, stained positive for C1q (Fig 3A), suggesting that complement activation may play a role in impairing NET degradation in MIS-C. G-actin is a natural inhibitor of DNase1 that has also been reported to impair NET degradation (Hakkim et al., 2010). Levels of G-actin in the samples from the Chilean MIS-C cohort were significantly elevated when compared to ctrls (Fig 3B), while they were not elevated in patients with CLL ( Fig 3B). Anti-NET autoantibodies (autoAbs) have been previously associated with impairments in NET degradation in conditions such as systemic lupus erythematosus, and these autoAbs have been reported in adult COVID-19 patients (Hakkim et al., 2010;Zuo et al., 2021a). Therefore, we tested for their presence in MIS-C or CLL samples. We detected IgG binding to NETs in CLL but not in MIS-C samples (Fig 3C), in association with for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ;https://doi.org/10.1101/2022 doi: medRxiv preprint 1 2 COVID-19 are associated with the presence of symptoms and can persist for several months post-initial infection.

NETs associate with disease severity in adult COVID-19.
To gain further insight into the possible role of NETs in the symptoms and complications of COVID-19, we analyzed multiple parameters that were specifically available for the adult COVID-19 Brescia cohort. We found that serum levels of citH3-DNA complexes were significantly elevated in patients with COVID-19 that were in severe or critical condition ( Fig   5A), those who required intensive care unit (ICU) admission (Fig 5B), those with pneumonia ( Fig 5C), and those who required high flow oxygen when compared to those with no need for oxygen supplementation (Table 2). Serum levels of citH3-DNA were not associated with sex, age, death, diabetes, cardiovascular disease, chronic heart failure, and other comorbidities ( Table   2). Of note, serum levels of citH3-DNA were significantly decreased in patients who developed COVID-19 and had underlying chronic hypertension, chronic kidney disease or history of solid malignancy (Table 2). In the adult patient population with COVID-19, we found that levels of serum citH3-DNA most consistently associated with disease severity, while levels of elastase-DNA followed less consistent and sometimes opposite trends compared to the citH3-DNA levels (Supplementary Table 2). 1 3 organ transplantation (Table 3 and Supplementary Table 3). Plasma elastase-DNA was also associated with congestive heart failure ( Fig 5F), while plasma citH3-DNA was associated with liver disease (Supplementary Table 3). Of note, levels of NET remnants were similar in adult and pediatric COVID-19 cohorts. Overall, levels of NET remnants were associated with specific disease manifestations and disease severity in adult subjects diagnosed with COVID-19.

NET degradation is impaired in adult patients with COVID-19.
We analyzed NET degradation capability of serum samples obtained from Italian adult COVID-19 patients. Similar to the pediatric population, impairments in NET degradation were significantly increased in the serum samples from adult COVID-19 patients when compared to ctrls (Fig 6A), and the impairment was significantly higher in symptomatic COVID-19 patients when compared to those who were asymptomatic at diagnosis (Fig 6A). In adults, 54% of the COVID-19 samples tested displayed impairments in NET degradation (Fig 6A-B). We investigated whether the lack of NET degradation persisted after acute infection period had passed. To address this, we tested the NET degradation capacity of serum samples from 20 COVID-19 patients at initial diagnosis and 3 months later. A significant improvement in NET degradation was observed 3 months after initial infection with SARS-CoV-2, with a reduction of non-degraders from 65 to 25% of the samples tested ( Fig 6C).
WGS analysis was also performed in adult patients to determine if there were putative genetic contributions of rare or common variants within genes associated with DNA degradation and their link to NET degradation impairments in adult COVID-19 patients from Italy. No common (minor allele frequency (MAF) >0.1) variants were detected with distribution toward degraders for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. During the COVID-19 pandemic, many SARS-CoV-2 variants have emerged (2021). Omicron (B.1.1.529) variant is of particular interest for its rapid spread across the world(Callaway, 2021).
Omicron variant harbors 37 mutations in the spike protein (Mannar et al., 2022). Although, Omicron seen to be more contagious, data indicate it is milder than other variants (Nealon and Cowling, 2022). Therefore, we hypothesized that unvaccinated adult patients infected with Omicron variant will display decreased NET levels when compared to those infected with earlier strains (Alpha). Indeed, citH3 and elastase-DNA complexes measured in plasma from unvaccinated Italian COVID-19 patients infected with the Omicron variant were significantly decreased when compared to those that had been infected with the original strain during the first peak of the pandemic (Fig 8 A-B). In addition, males infected with Omicron variant (but not females) displayed significantly lower levels of plasma citH3-DNA complexes when compared to those infected with the original strain ( Fig 8C). We found that plasma levels of citH3-DNA complexes were significantly reduced in patients with the Omicron variant that were in critical condition (Fig 8D), those who required ICU admission (Fig 8E), those with hypertension ( Fig   8F), and those who required high flow oxygen when compared to those infected with the earlier variant. Overall, these results indicate that different variants of the virus are associated with differences in the levels of circulating NETs and that infection with the Omicron variant is associated with lower levels of these structures when compared to patients infected with earlier strains.
for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Discussion
Increasing evidence supports a detrimental role of NETs in COVID-19 pathogenesis. NETs and NET remnants have been detected in adult COVID-19 lung tissues and plasma samples, respectively (Barnes et al., 2020;Zuo et al., 2020). Our findings expand prior work by showing a link between NETs and infection with SARS-CoV-2 in children with MIS-C and CLL, as well as an association between circulating NETs and clinical outcomes in pediatric and adult patients from different geographic locations.
In the present study, we showed that pediatric patients diagnosed with MIS-C and CLL displayed elevated amounts of circulating NETs in serum or plasma and in tissue. Impaired NET degradation was also evident and associated to a variety of factors that include complement activation, presence of anti-NET autoAbs and a natural DNAse1 inhibitor, G-actin. As G-actin levels decreased as the disease improved, this suggests that induction of G-actin may be an acute response phenomenon that occurs in patients with severe COVID-19 who present with impaired NET degradation. Although CLL has remained a controversial entity, the presence of NET remnants across the spectrum of those with confirmed COVID-19 infection in this study supports a SARS-CoV-2 etiology. NET remnants were associated with comorbidities present in pediatric patients and there was geographic variability in these findings. For instance, citH3-DNA levels were elevated in MIS-C samples obtained from Chile, but not from Italy and similar differences in NET degradation capabilities were also observed. While the levels of elastase-DNA were elevated in CLL samples from the United States, they were more evidently elevated in those samples obtained from Italy. While technical factors associated with sample collection and for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022.
1 8 processing at various centers could in theory contribute to these differences, the previous observations that SARS-CoV-2 and various COVID-19-associated host factors can directly induce NET formation in COVID-19(Middleton et al., 2020) support that possibility that environmental or yet unidentified genetic factors, including SARS-CoV-2 variants may modulate how neutrophils respond to the infection and associated inflammatory milieu. It will also be important to assess in the future whether the MIS-C cohort from Chile had stronger associations with autoimmunity features than the cohort of MIS-C patients from Italy, and whether the presence of NETs or NET-associated Abs may show an association with these clinical differences. However, as mentioned in results section, to date none of the patients with MIS-C in Italy or Chile followed in this study have developed persistent autoimmunity.
NETs are dismantled by endogenous DNases that can regulate NET-driven thrombosis. (Barnes et al., 2020;Hakkim et al., 2010;Zuo et al., 2021b) Impairments in NET degradation have been shown to increase endothelial damage, (Carmona-Rivera et al., 2015) associate with thrombus formation, (Middleton et al., 2020;Wolach et al., 2018;Zuo et al., 2021b) organ dysfunction, inflammation and autoimmunity (Knight et al., 2012).We found that pediatric subjects diagnosed with MIS-C or CLL displayed decreased NET degradation that, in most cases, could be restored with exogenous DNase1 in vitro. Genetic and environmental factors contribute to decreased DNase activity or efficiency. Patients harboring mutations in DNASE1 are at higher risk of developing lupus (Hartl et al., 2021;Yasutomo et al., 2001). However, in the WGS analysis, we did not find genetic drivers of impaired nuclease activity, suggesting that environmental factors, such as differences in microbiome composition, UV light exposure, pollutants, etc., may be for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 involved. Certainly, assessments of larger cohorts of patients will be required to fully exclude genetic drivers of these abnormalities.
Complement activation, presence of natural DNase1 inhibitors, and autoAbs have been reported to contribute to impairments in NET degradation in inflammatory and autoimmune conditions (Hakkim et al., 2010;Leffler et al., 2012;Zuo et al., 2021a). We found that impairments of NET degradation in MIS-C patients were associated with the presence of the natural DNase-1 inhibitor, G-actin, and with enhanced ability for serum C1q to deposit in NETs.
In contrast, anti-NET autoAbs were primarily associated with impairments in NET degradation in subjects with CLL. These results highlight the complexity of neutrophil responses following exposure to SARS-CoV-2 and the associations with different disease manifestations. Addition of exogenous DNase1 to MIS-C and CLL samples restored NET degradation capabilities in most samples, suggesting that treatment with exogenous DNases could be of benefit to decrease NETs in COVID-19 patients. Notably, aerosolized DNases treatment have been evaluated in clinical trials as a putative therapy in this disease.
Consistent with previous work, markers of NETs were elevated in adult patients with COVID-19(Zuo et al., 2020). Symptomatic adult COVID-19 samples obtained from Italy during the peak of the pandemic in Europe in early 2020, displayed elevated circulating NETs, while samples from asymptomatic patients did not. While the mechanisms promoting enhanced NET formation in COVID-19 remain to be further determined, these results provide a putative link between NETs and symptomatic COVID-19. COVID-19 associated NET formation may involve other mechanisms beside direct infection of neutrophils by SARS-CoV-2 that explain the lack of NET for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ;https://doi.org/10.1101/2022 doi: medRxiv preprint 2 0 markers found in infected asymptomatic COVID-19 patients. Furthermore, asymptomatic subjects did not display significant impairments in NET degradation, nor the presence of factors that can interfere with the dismantling of the NETs. In contrast, NETs were elevated in symptomatic COVID-19 patients, and they remained elevated at least 3 months after infection diagnosis. Whether this protracted resolution of NET dysregulation is associated with long-COVID symptoms or other chronic complications remains to be determined and should be the focus of future work. Furthermore, NETs were present in extrapulmonary COVID-19 tissues such as heart, liver, kidney, and spleen. These results may implicate NETs in extrapulmonary manifestations seen in COVID-19 patients, even after clearing the virus.
Several SARS-CoV-2 variants have emerged during COVID-19 pandemic. Omicron is the most recent variant of SARS-CoV-2 reported in late 2021(Callaway, 2021) and was identified as variant of concern because of its rapid spread (Mannar et al., 2022), albeit associated to milder symptoms than other variants(Nealon and Cowling, 2022). NET remnants from adult unvaccinated patients infected with Omicron variant in Italy were significantly reduced when compared to COVID-19 patients infected with the variant of SARS-CoV-2 that affected Italy early in the pandemic. These results could suggest that lower NET formation induced by this variant may explain in part the milder symptomatology. Alternatively, the milder inflammatory phenotype induced by this strain may account for downstream effects on neutrophils, limiting their ability to NET following this infection. Future studies will be needed to further expand the understanding on how different viral strains modulate neutrophil biology, whether some of these differences explain the geographic variation in NET levels and clearance, and the overall implications of these variations in the reported findings.
for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 Various preexisting comorbidities have been associated with higher morbidity and mortality in adult and pediatric subjects that develop COVID-19(Ejaz et al., 2020;Yang et al., 2020). In our study, there was no consistent association between specific comorbidities and levels of NETs in adult and pediatric populations. Pericarditis, kidney damage, neurologic, and psychiatric manifestations are among the clinical manifestations of a subset of the COVID-19 patients (Ejaz et al., 2020;Khaddaj-Mallat et al., 2021;Vinayagam and Sattu, 2020;Yang et al., 2020). While NETs have been detected in lung samples in COVID-19, it remains to be better characterized whether NETs in extrapulmonary tissues during and after COVID-19 in adults and pediatric patients are associated with prognosis, disease manifestations, or development of long COVID.
Here, we were able to detect citH4 positive structures in skin from pediatric patients affected by CLL and in autopsy tissues from adult subjects who died from severe COVID-19. Of note, the lung, kidney, and spleen were the organs with most NET detected, followed by the heart.
Enhanced NET formation or diminished NET clearance may increase the risk of organ damage, and the presence of NETs in these extrapulmonary tissues may link these structures with other complications associated with COVID-19. As the biological significance of NETs during COVID-19 is still not completely elucidated, future studies should investigate the potentially deleterious role of NETs in extrapulmonary tissues that may explain part of the pathophysiology of severe COVID-19.
Limitations of the study are primarily derived from the heterogeneity of the cohorts. The clinical centers sites did not all collect the same clinical characteristics during the peak of the pandemic, limiting in some cases the comparisons among groups, as mentioned above. Furthermore, at this point, we do not have comprehensive details regarding the development of chronic for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 complications and/or long-COVID ensuing after COVID-19 infection in these cohorts, which would allow us to further elucidate the impact of enhanced NET formation in this condition. It was difficult to assess the impact of specific therapies on NET formation/degradation as detailed information about medication treatment at each center was not available for our analysis.
Additionally, we were limited in the collection of samples from patients infected with different SARS-CoV-2 variants. Despite these limitations, we were able to work with heterogenous and geographically diverse cohorts in both pediatric and adult populations.
In summary, our findings support a link between NET dysregulation and pediatric manifestations of COVID -19 in association with specific disease manifestations. Pediatric and adult symptomatic COVID-19 patients displayed impaired NET degradation that did not appear to be genetically driven. These results highlight a putative pathogenic role of NETs and impairments in NET degradation in pediatric and adult subjects affected by COVID-19.
for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  cohorts was defined as follows: 1. asymptomatic, 2. mild, 3. moderate, 4. severe and 5. critical as per the NIH COVD-19 treatment Guidelines (https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf).
For CLL samples obtained from the University of Wisconsin-Madison, patients were prospectively enrolled and consented after the start of the COVID-19 pandemic. Those with prior history of seasonal pernio were included due to speculation for a shared genetic susceptibility with pandemic-associated pernio with other circulating viruses as a possible trigger. Affected skin biopsy specimens were obtained from those requiring tissue diagnosis for standard of care.
for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Samples from healthy age, gender and sex-matched ctrls without history of COVID-19 symptoms or PCR-confirmed infection were used for serological studies.

Post-mortem tissue collection.
Autopsies were performed and tissues were collected as previously described (Huang et al., 2021b) in the National Cancer Institute's Laboratory of Pathology at the NIH Clinical Center, coordinated by the NIH COVID-19 Autopsy Consortium and following consent of the legal next of kin.

Whole Genome Sequencing (WGS)
Genomic DNAs were extracted from patients' whole blood by an automated nucleic acid sample preparation instrument (Qiagen QIAsymphony SP) using the QIAsymphony DNA Midi Kit.
DNA samples were then quantified using a fluorescence dye-based assay (PicoGreen dsDNA reagent) by a microplate reader (Molecular Devices SpectraMax Gemini XS). WGS libraries were generated from fragmented DNA using the Illumina TruSeq DNA PCR-Free HT Library Preparation Kit with minor modifications for automation (Hamilton STAR Liquid Handling System). Sequencing libraries were quantified using the KAPA qPCR Quantification Kit (Roche Light Cycler 480 Instrument II) and combined as 24-plex pools after normalization and sequencing on an Illumina NovaSeq 6000 using a S4 Reagent Kit (300 cycles) using 151+8+8+151 cycle run parameters. Primary sequencing data was demuxed using the Illumina HAS2.2 pipeline and sample-level quality control for base quality, coverage, duplicates, and for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.02.24.22271475 doi: medRxiv preprint contamination was conducted. All sequencing date were then processed with Burrows-Wheeler Aligner (BWA) and the Genome Analysis Toolkit (GATK) best-practice pipeline for alignment and variant calling. Whole genome association data were deposited at dbGaP under accession number phs002245.v1.p1

NET-complexes ELISA
A 96-well plate was coated with rabbit polyclonal anti-citH3 (Abcam ab5103) or anti-neutrophil elastase (Calbiochem, 481001) at 2.5 ug/mL in PBS overnight at 4˚C. Wells were blocked in blocking buffer (1% BSA in PBS) at RT for 1 h. Plasma or serum were diluted 1: 100 in blocking buffer and incubated overnight at 4˚C. After washing three times with washing buffer (0.05% Tween in PBS), samples were incubated with mouse monoclonal anti-double stranded DNA antibody (EMD Millipore, Clone BV16-13, MAB030) at 1:100 in blocking buffer for 1 h at RT. Plate was washed three times and incubated with goat anti-mouse conjugated HRP antibody (1:10,000) (Bio-Rad, 1721012) for 1h at RT. Wells were washed five times with 0.05% Tween in PBS followed by the addition of 100 uL of TMB substrate (Sigma Aldrich) and 50 uL of 0.16M sulfuric acid stop solution (Sigma Aldrich). The absorbance was measured at 450 nm on an ELISA plate reader.

NET degradation assay
Control neutrophils were resuspended in un-supplemented RPMI (1x10 6 cells/mL) and were stimulated with PMA (Sigma) (500ng/mL). A hundred microliters/ well were plated in a 96-well black plate and incubated for 4 h at 37 o C to induce NETs. Following stimulation, formed NETs were treated with 5% serum from either healthy ctrls or patients for 16 h at 37 o C. Wells were for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.02.24.22271475 doi: medRxiv preprint stained with 0.2 uM Sytox green (ThermoFisher) for 5 min. Plate was read using a microplate reader (Synergy HT, Bio-Tek). Results are presented as relative fluorescence units (RFU). Wells were visualized to corroborate the presence or the absence of NETs using the ZOE microscope.

Detection of NETs in tissue specimens.
Parafilm embedded samples were processed as previously described.(Carmona-Rivera et al.,

2017)
Immunofluorescence Neutrophils were fixed in 4% paraformaldehyde in PBS overnight at 4°C, washed, and blocked with 0.2% porcine gelatin (Sigma, St. Louise, MO) for 30 min, then incubated with primary antibody ( anti-C1q or patient serum) for 1 h in a humid chamber at 37°C. Coverslips were then washed three times and incubated 30 min with secondary antibody at 37°C. Nuclei were counterstained with 1:1000 Hoechst at RT. After washing three more times, coverslips were mounted on glass slides using Prolong-gold solution (Invitrogen). Images were acquired on a Zeiss LSM 780 confocal microscope.

Anti-DNase1, anti-DNase1L3 and NET Ab detection.
A 96-well plate was coated with 2.5 ug/mL of PMA-generated NETs, recombinant DNase1 (Abcam) or DNase1L3 (MyBiosource) in PBS overnight at 4°C. Plate was blocked with 1% BSA for 1 h at RT. One microgram of total protein from control or patient skin samples or diluted (1:200) sera were incubated overnight at 4°C. Plate was washed 4 times with 0.05% PBS-for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.02.24.22271475 doi: medRxiv preprint Tween (PBS-T). Horseradish conjugated-anti-human IgG secondary antibody (1:5,000; Sigma) was incubated for 1 h at RT, followed by 5 washes with PBS-T. Plate was developed in the presence of TMB and read at 450 nm using a microplate reader (Synergy HT, Bio-Tek). Results are presented as optical density (OD) index (ratio of the OD in the patient serum to the mean OD in healthy control serum).

G-actin ELISA
Serum G-actin levels were detected using commercially available G-Actin ELISA kit (MyBioSource) following the manufacturer's instructions.

Statistical analysis
Data was processed using R version 4.0 and the tidyverse package. All figures and associated statistics were performed using GraphPad Prism Version 8.1.1 (La Jolla, CA). Mann-Whitney U test was used for pair-wise comparisons. One-way analysis of variance (ANOVA) Kruskal-Wallis test (Dunn's multiple comparison test) was used to compare parameters among groups.
Pearson correlation was used for all non-categorical statistics. All analyses were considered statistically significant at p < 0.05. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10. 1101/2022 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  (citH4, red) and DNA (blue) was performed in skin tissue obtained from 3 CLL patients and one ctrl (F) Levels of citH3-DNA complexes were correlated with the absence or present of heart medication/pressors, pneumonia or shock in Chilean MIS-C patients. Results are the mean +/-SEM. Mann-Whitney analysis were performed *p< 0.05, **p<0.01.Ctrl: controls; OD: optical density; *p<0.05, ** p<0.01, ****p<0.001.
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10. 1101/2022 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.02.24.22271475 doi: medRxiv preprint Figure 2. Impaired NET degradation in MIS-C and CLL samples. NET degradation capabilities were measured in serum or plasma from MIS-C samples obtained from (A) Italy (MIS-C n=12, control n= 12) and Chile (MIS-C n=27) and CLL obtained from (B) Italy (CLL n= 27, control n= 12) and US (n=5). Results are the mean +/-SEM. Kruskal-Wallis analysis was performed. (C) Pie charts representing the proportion of degrader (white) and non-degrader (black) per cohort. (D) Representative images of PMA-generated NETs incubated with serum or plasma from control or MIS-C, CLL patients. DNA is detected by Sytox green and scale bar is 100um. (E) NET degradation capabilities were measured in serum or plasma of MIS-C (n=7) and CLL (n= 4) samples in the presence or absence of recombinant DNase 1. Samples within dashed circle are those that did not respond to treatment with DNase1. Kruskal-Wallis analysis was performed. (F) Representative images of PMA generated NETs incubated with serum or plasma from MIS-C, CLL patients in the presence or absence of recombinant DNase 1. DNA is detected by Sytox green and scale bar is 100um; *p< 0.05, **p<0.01, ***p<0.001, ****p<0.0001 for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Results are the mean +/-SEM. Mann-Whitney was used. *p<0.05, ***p<0.001, ****p<0.0001. OD: optical density.
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.02.24.22271475 doi: medRxiv preprint (COVID-19 n=153, asymptomatic n= 26, control n=12), pie chart depicting the proportion of degrader (white) and non-degrader (black). Results are the mean +/-SEM. Kruskal-Wallis analysis was performed. (B) Representative images of PMA generated NETs incubated with serum from control or COVID-19 patients. DNA is detected by Sytox green and scale bar is 100um. (C) NET degradation capabilities were assessed in twenty patients at initial infection and 3 months (3 mo) after. Pie charts depicting the proportion of degrader (white) and non-degrader (black) at initial and 3 months after infection with SARS-CoV-2. Kruskal-Wallis analysis was performed. (D) Confocal images of immunofluorescence analysis of C1q deposition (red) in PMA-generated NETs after incubation with serum from symptomatic and asymptomatic COVID-19 patients. DNA is detected in blue and scale bar is 10um. Pearson correlation analysis of (E) levels of anti-NET, (F) anti-DNase1, (G) anti-DNase1L3 Abs and (H) G-actin measured in serum from COVID-19 patients with NET degradation capabilities (DNA). (I) Levels of serum G-actin in COVID-19 patients (n=20) at initial and 3 months after diagnosis of infection with SARS-CoV-2. Kruskal-Wallis analysis was performed. (J) Pearson correlation analysis of G-actin measured in serum from COVID-19 patients at initial and 3 months after infection with SARS-CoV-2 with NET degradation capabilities (DNA). *p< 0.05, **p<0.01, ****p<0.0001; ctrl:contrl; mo:months; RFU: relative fluorescence units.
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10. 1101/2022 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

References.
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.02.24.22271475 doi: medRxiv preprint  C  o  n  s  i  g  l  i  o  ,  C  .  R  .  ,  N  .  C  o  t  u  g  n  o  ,  F  .  S  a  r  d  h  ,  C  .  P  o  u  ,  D  .  A  m  o  d  i  o  ,  L  .  R  o  d  r  i  g  u  e  z  ,  Z  .  T  a  n  ,  S  .  Z  i  c  a  r  i  ,  A  .  R  u  g  g  i  e  r  o  ,  G  .  R  .   P  a  s  c  u  c  c  i  ,  V  .  S  a  n  t  i  l  l  i  ,  T  .  C  a  m  p  b  e  l  l  ,  Y  .  B  r  y  c  e  s  o  n  ,  D  .  E  r  i  k  s  s  o  n  ,  J  .  W  a  n  g  ,  A  .  M  a  r  c  h  e  s  i  ,  T  .  L  a  k  s  h  m  i  k  a  n  t  h  ,   A  .  C  a  m  p  a  n  a  ,  A  .  V  i  l  l  a  n  i  ,  P  .  R  o  s  s  i  ,  C  .  S  .  T  e  a  m  ,  N  .  L  a  n  d  e  g  r  e  n  ,  P  .  P  a  l  m  a  ,  a  n  d  P  .  B  r  o  d  i  n  .  2  0  2  0  .  T  h  e   I  m  m  u  n  o  l  o  g  y  o  f  M  u  l  t  i  s  y  s  t  e  m  I  n  f  l  a  m  m  a  t  o  r  y  S  y  n  d  r  o  m  e  i  n  C  h  i  l  d  r  e  n  w  i  t  h  C  O  V  I  D  -1  9  . C e l l H u a n g , C .
, for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  e  r  r  e  r  a  -G  u  e  r  r  a  ,  a  n  d  S  .  L  a  k  s  h  m  i  n  r  u  s  i  m  h  a  .  2  0  2  0  .  M  u  l  t  i  -S  y  s  t  e  m   I  n  f  l  a  m  m  a  t  o  r  y  S  y  n  d  r  o  m  e  i  n  C  h  i  l  d  r  e  n  (  M  I  S  -C  )  F  o  l  l  o  w  i  n  g  S  A  R  S  -C  o  V  -2  I  n  f  e  c  t  i  o  n  :  R  e  v  i  e  w  o  f  C  l  i  n  i  c  a  l   P  r  e  s  e  n  t  a  t  i  o  n  ,  H  y  p  o  t  h  e  t  i  c  a  l  P  a  t  h  o  g  e  n  e  s  i  s  ,  a  n  d  P  r  o  p  o  s  e  d  M  a  n  a  g  e  m  e  n  for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.